vide evidence that residues in the a3 domain of class I molecules on the target cell contribute to a conserved determinant that is recognized by the Lyt-2 molecule on CTL . Several lines of evidence support this conclusion: (a) mAbs to determinants in the a3 domain of H-2Ld or H-21)d inhibit the generation of primary CTL in vitro but do not inhibit the generation of and only partially inhibit the function of secondary CTL ; (b) secondary CTL populations generated in the presence of antibodies specific for the a3 domain of the stimulating antigen, in contrast to primary or secondary CTL generated in the absence of mAb, are only weakly inhibited by antibody to Lyt-2 ; (c) treatment of mice with graft-specific antibodies to both a3, as well as al/a2 domain determinants is necessary to enhance the survival of skin grafts ; (d) target cells expressing a mutant H-2Dd molecule that possesses a single amino acid substitution in the a3 domain are not killed by CTL generated in a primary in vitro response, but are killed by the Lyt-2-independent CTL population generated by secondary stimulation in the presence of antibody to the a3 domain of H2Dd ; and (e) cells expressing the a3 mutant D d molecule fail to elicit a primary in vitro cytotoxic response. In total, these results identify residues in the class I a3 domain that are involved in Lyt-2 recognition and furthermore suggest that mAbs to determinants in the a3 domain can be used in vivo and in vitro to block this Lyt-2-dependent recognition .
Materials and Methods
Mice. BALB/cKh (Kd, Dd, Ld), BALB/c-H-2 dms (Kd, Dd), C3H (Kk, Dk), and (C3H .OL (Kd, Dk) x BALB.K (K k , Dk))Fl were bred in the animal facility of Dr. Donald C. Shreffler, Washington University School of Medicine, St. Louis, MO.
Antibodies. The mAbs used have been previously described . Briefly, antibody 30-5-7 was derived in dm2 mice and was shown to recognize an epitope in the al/a2 domain of Ld, whereas antibody 28-14-8 was derived from C3H mice and was shown to recognize the a3 domain of Ld and several other D region-encoded molecules (15, 16) . Antibodies 34-5-8 and 34-2-12 were both derived from C3H mice and were shown to recognize the al/a2 and a3 domains of Dd, respectively (16, 17) . Antibody 3-83 was derived from BALB/c and recognizes H-2k antigens (18) . All five of the above mAbs have the y2a isotype and when grown as an ascites contained a titer of antibody of "30,000, as measured by dye-exclusion cytotoxicity (data not shown) . They also have comparable affinities based on analysis by flow microfluorometry (FMF) . 1 The mAbs 53-6.7 and 53-7 .3 were both derived from the rat, have the y2a isotype, and recognize Lyt-2 and Lyt-1, respectively (19) . All antibodies were analyzed by FMF on splenic T cells and/or target cell lines and were titered in CTL assays before use in the experiments reported here.
Skin Grafting. Skin grafts were performed as described previously (20) . Full thickness donor tail skin grafts were trimmed to -0 .5 x 1 .0 cm . Appropriately sized graft beds were prepared on the recipient's dorsal thorax by carefully removing skin with scissors without disturbing the panniculus carnosus . All grafts were male to male. The transplanted tissues were protected with a gauze dressing and a plaster bandage for 7 d. Grafts were scored as rejected when <10% of the donor tissue was viable by gross inspection .
Culture of Cell Lines. All ofthe cell lines used as targets were grown in DME (high glucose) supplemented with L-glutamine, pyruvate, and 10 % FCS . P815 is a mouse mastocytoma isolated from a DBA/2 mouse. R8 .15 .28 (Dd glu) and L.Dd .28 express the transfected wild-type Dd gene and R8.15 .29 (Dd lys) and L.Dd .29 express the transfected a3 mutant Dd gene as previously described (14) . The R8 .15 cell line into which the genes were transfected was iso-lated from R8 (H-2d x H-24)F, by immunoselection and does not possess H-2d genes (21) . The L.Dd.28 and L.Dd.29 cell lines were produced by transfection into L cells, a fibroblast cell line originating in C3H (H-2') mice. The R8.15 transfected cell lines were cultured in the presence of 400 ug/ml G-418 sulfate antibiotic (Sigma Chemical Co., St. Louis, MO) and the L cell-transfected cell lines were cultured in the presence of 200 jig/ml G-418 sulfate antibiotic . Cells were used for targets during log phase of growth.
Fluorescence Labeling ofCells and Analysis by FMF. For fluorescence analysis, cells were washed, labeled, and analyzed in HBSS lacking phenol red but containing 0.2% BSA and 0.1% sodium azide (FMF medium). 4 x 105 cells were placed in each well of a round-bottomed microtiter plate (Flow Laboratories, Inc., McLean, VA), washed two times, and incubated for 30 min at 4'C in the presence of a saturating concentration of mAb . The cells were washed two times and resuspended in a saturating concentration of fluorescein-conjugated, affinitypurified F(ab')2 fragment of goat anti-mouse IgG, Fc specific, or of goat anti-rat IgG (CooperBiomedical, Inc., Malvern, PA) . The cells were incubated for 30 min at 4°C then washed three times and resuspended in FMF medium containing 10 Rg/ml propidium iodide, used to exclude dead (red fluorescent) cells from analysis.
Cellswere analyzed on a FRCS IV (Becton &Dickinson Co., Mountain View, CA) equipped with an argon ion laser tuned to 488 nm and operating at 300 mW of power. Fluorescence histograms were generated with logarithmic amplification of fluorescence emitted by single viable cells . Each sample analyzed comprised a minimum of 5 x 104 cells . Cells labeled with only the fluorescein-conjugated antibody were always included as controls .
Generation of H-2Ls-or H-21)4-sped CTL . Responding spleen cells (7.5 x 106) were cocultured with stimulating spleen cells (3.5 x 106, 2,000 rad), L cells (5 x 104, 10,000 rad) or medium alone in 24-well Linbro trays (Flow Laboratories, Inc.) containing 2 ml RPMI 1640 medium (Mediatech, Washington, DC) supplemented with L-glutamine, sodium pyruvate, nonessential amino acids, penicillin, streptomycin, 5 x 10-5 M ß-mercaptoethanol, and 10% FCS (HyClone Laboratories, Logan, UT) . After 5 d at 37°C in the presence of 5ojo C02, effector cells were harvested, washed, and resuspended in RPMI 1640 medium supplemented with 10% FCS (RPMI-FCS). For those experiments that included mAbs during the 5-d sensitization, 10' stimulator spleen cells were preincubated with 500 1r1 ofmAb ascites (1 :10 dilution in culture medium) for 30 min on ice . They were washed and resuspended in fresh medium containing the appropriate antibody before addition to the culture wells. The final concentration of antibody in the culture was 1%.
"Cr-release Assay. 3 x 106 target cells were labeled with 150-300 gCi of"Cr (Na5'CrO4, 10-25 mCi/ml; Amersham Corp., Arlington Heights, IL) in 300 wl of RPMI-FCS for 45 min at 37°C in 5% C02. Cells were washed twice and 104 cells were added to the wells of round-bottomed microtiter plates. For antibody blocking studies, 50 Rl of antibody was preincubated with 50 ul of target cells or 100 wl of effector cells or medium for 20 min at 37°C. The remaining cells were added to a final volume of 200 pl per well, the plates were spun at 50 g for 1 min and incubated in a humidified atmosphere at 37°C, 5% C02. At the end of 4 h the plates were spun at 800 g for 5 min and 100 ul of supernatant was counted in a Searle automatic gamma counter (Searle Analytic, Des Plaines, IL). The mean of triplicate samples was calculated and percent 5'Cr release was determined according to the following equation : Percent "Cr release = 100 x [(experimental "Cr release -control "Cr release)/(maximum "Cr release -control 51Cr release)], where experimental "Cr release represents counts from target cells mixed with effector cells, control "Cr release represents counts from target cells incubated in medium alone (spontaneous release), and maximum "Cr release represents counts from target cells exposed to 5% Triton-X100 . For the data presented in this paper the SEM percent specific lysis was <5% of the value of the mean.
Results
Antibody to the 0 Domain of H-2Ld Inhibits Lysis by Primary, but not Secondary, CTL lbpulations. To delineate the involvement of the different domains of class I molecules in CTL recognition, we examined the ability of antibodies specific for either the Effector To Target Ratio al/a2 or the a3 domain to inhibit lysis by Ld-specific CTL. Spleen cells from BALB/c-H-2 1'" 2 (dm2) mutant mice that have undergone a deletion of the Ld gene (22) were stimulated in vitro with spleen cells from BALB/c mice . Antibodies to either the al/a2 (30-5-7) or the a3 (28-14-8) domain strongly inhibited lysis of target cells by these Ld-specific CTL derived by primary in vitro stimulation (Fig. 1 A) . We next examined whether these same antibodies would inhibit anti-Ld CTL generated in a secondary response. Dm2 mice were primed in vivo by grafting of BALB/c skin . 1-2 wk after rejection, spleen cells from these mice were restimulated in vitro. Although we refer to this population as secondary CTL, it is possible that some unprimed T cells are also stimulated and therefore some primary CTL may be present. Lysis of Ld-positive targets by this secondary CTL population was inhibited by the 30-5-7, but not the 28-14-8 antibody (Fig. 1 B) . There are several explanations for the inhibition of CTL function by antibodies including: (a) binding of the antibody creates a steric hindrance for CTL recognition and/or killing, (b) binding ofthe antibody alters the conformation ofallodeterminants recognized by CTL, or (c) the antibody binds to residues that are necessary for CTL recognition. While it is usually difficult to distinguish between these alternatives, the observation that 28-14-8 did not inhibit the activity of secondary CTL indicated that this antibody did not cause 10 Survival of Ld-disparate (A) or Dd-disparate (B) skin grafts in mice given antibodies to MHC class I determinants . Animals received either 0.2 ml of one antibody or 0.1 tnl of both antibodies at the times indicated starting with the day of grafting. The numbers in parentheses represent the number of animals in each treatment group.
conformational changes in allodeterminants, nor a steric hindrance, for secondary CTL activity. This finding also raised the possibility that the inhibition by 28-14-8 of primary CTL activity was because this antibody bound a determinant that was recognized by primary CTL, but not by secondary CTL .
Antibodies to Either the al/a2 or the a3 Domain ofH-2Ld Inhibit the Generation ofPrimary CTL In Vitro. Having established that there was a difference between primary and secondary anti-Ld CTL in the susceptibility to inhibition by the a3 domain antibody when added during the effector phase, we next examined the effect of antibodies added during the sensitization phase. Addition of the 28-14-8 (a3 domain) or the 30-5-7 (al/a2 domain) antibodies during the 5-d in vitro sensitization abrogated the generation of Ld-specific primary CTL (Fig. 1 C) . To examine whether these antibodies would also inhibit the generation of secondary CTL we tested the effect of antibodies added during in vivo priming.
Treatment with a Combination ofAntibodies to al/a2 and a3 Epitopes ofLd has a Synergistic Effect on Skin Graft Enhancement. Priming ofCTL in vivo can be achieved either by the injection ofallogeneic cell suspensions or by performing an allograft . We decided to perform allografting as it allowed us to monitor the effect of antibodies on the priming ofCTL, not only through the subsequent analysis ofprimed CTL populations, but also by the impact ofantibodies on the survival ofthe graft. The injection ofantibodies to class II MHC molecules expressed on an allograft can be very effective in enhancing skin graft survival (23) . As the antibodies to H-2Ld inhibited the generation and the activity of CTL in vitro, a similar effect in vivo would enhance the survival of H-2Ld-disparate skin grafts . To confine the disparity to H-2Ld, dm2 mice received a graft from BALE/c mice. Some of the skin-grafted animals were injected with antibody to either the al/a2 domains (30-5-7), or the a3 domain (28-14-8) of Ld or with both antibodies. Animals that received either of the two antibodies on days 0, 2, and 4 showed a slight enhancement of skin graft survival compared with animals that received no antibody or an irrelevant antibody (anti H-2Kk) on days 0, 2, and 4 ( Fig. 2 A) . Graft survival was enhanced more when animals received both antibodies together on days 0, 2, and 4 ( Fig. 2 A) . This finding is consistent with a recent report by Lems et al. (24) . Since both antibodies were found to have a comparable in vivo half-life of N3 wk (cytotoxicity data not shown), a regimen ofweekly antibody injections was also tested. When the injections ofanti- body were given weekly, dramatic synergism between the two antibodies was observed ( Fig. 2 B) . About 40% (11/25) of the mice that received both antibodies had viable tissue grafts after 100 d. In contrast, mice that received only one of the H-2Ld antibodies rejected their grafts before 24 d. A similar enhancement ofgraft survival by treatment with both H-2Ld antibodies was also seen in (CM x dm2)Ft mice grafted with BALB/c skin. In this experiment the injections of antibody were given on days 0, 2, and 4 and the injection of both antibodies together enhanced the survival of the graft in these Ft mice even more than similarly timed injections given to dm2 mice (Figs . 3 A and 2 A). The finding that enhancement appears easier to obtain in the Fl mice as compared with dm2 mice could be accounted for by either (a) a weaker anti-Ld response in the Fl due to elimination of H-2k-crossreactive CTL clones or (b) the matching of Ig allotype/idiotype in the Ft since 28-14-8 is a C3H-derived antibody. In addition to examining the effect of H-2Ld antibodies on the survival of H-2Ld-disparate grafts we also investigated whether a combination of antibodies to al/a2 and a3 H-2Dd determinants could enhance the survival of H-2Dd-disparate grafts . To confine the disparity to H-2Dd determinants, (C3H.OL x BALB.K)F1 recipients were grafted with dm2 skin. Some of these animals received either the 34-2-12 antibody (specific for a3 of Dd), or the 34-5-8 antibody (specific for al/a2 of Dd), or a combination of the two antibodies on days 0, 2 and 4. Antibody to either the al/a2 or a3 domains alone caused only slight enhancement of skin graft survival, whereas a combination of the two antibodies had a synergistic effect and resulted in prolonged graft survival (Fig. 3 B) . This synergism between a1/a2 and a3 domain antibodies in the prolongation of either H-2Ld or H-2Dd-disparate skin grafts demonstrated that regimens using combinations ofantibodies to class I can enhance class I-disparate skin grafts . This finding is in contrast to previous studies in which antibodies to class II but not class I antigens enhanced allograft survival (23) . In addition, these data raise the possibility that recognition of both the al/a2 and a3 domains of the class I molecule are involved in allograft rejection .
In Vitro Ld-speck CTL Responses of Mice Injected with Antibodies to H-2Ld. To delineate the mechanism of the synergistic effect of these antibodies on skin graft enhancement, antibody-treated mice were tested for the generation ofCTL in vitro. Dm2 mice that were grafted with BALB/c skin (anti-Ld) and had received either no antibody, one antibody, or both antibodies (28-14-8 and 30-5-7) were tested for their ability to generate Ld-specific CTL in vitro. From animals treated with a single antibody, cultures were initiated at least 3 wk after graft rejection, and from animals 
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FIGURE 5 . Antibody blocking of Ld-specific (dm2 anti-BALB/c) CTL generated from primary and secondary in vitro cultures . The secondary cultures were generated after skin graft priming (C . Some of the skin-grafted animals received 28-14-8 on the day of grafting and weekly until rejection (C) and 28-14-8 was also included in some of the cultures from the antibody-treated animals (D) . The antibodies included in the CTL assay were 3-83-negative control (A), 28-14-8 (O), 30-5-7 ( " ), and 53-6 .7 (Q) . Antibody 53-7.3 was also included as a negative control and lysis in the presence of this antibody was not different from lysis in the presence of the 3-83 antibody control . Unstimulated control cells from each group were included and lysis was zero. Spontaneous release from the P815 target cells was 10.5 %.
that received both antibodies cultures were initiated from mice that possessed a viable graft at least 5 wk after grafting. Spleen cells from mice treated with either 28-14-8 or 30-5-7, or both antibodies together, generated anti-L d CTL after in vitro stimulation. The CTL response of skin-grafted animals that received 28-14-8 in vivo (Fig. 4) was indistinguishable from that of skin-grafted animals that did not receive any antibody (data not shown), but was greater than the response from animals that received either 30-5-7 alone or together with 28-14-8 (Fig. 4) . It is interesting that animals treated with both antibodies and showing no visible sign of graft rejection were able to generate an in vitro anti-L d CTL response. In addition, discontinuation of the weekly antibody treatments leads to rejection of the grafts (data not shown) .
In Vivo and In Vitro Treatment with a3 Domain-specific mAb Enhances the Generation of Lyt-2-independent CTL . The data presented in Figs . 1-4 suggest that antibodies to either al/a2 or a3 H-2Ld determinants can block the in vitro generation of alloreactive CTL from nonimmune mice ; however, both antibodies are required to prolong skin graft survival in vivo . In addition, spleen cells from skin-grafted mice treated with either, or both, of the H-2Ld antibodies, could be stimulated in vitro to generate anti-Ld CTL. We therefore examined whether the addition of H-2Ld antibodies in vitro would inhibit the generation of anti-Ld CTL from antibody-treated, skin-grafted mice . As shown in Figs . 5 (A and B) and i (A and B), antibody to the a1/a2 domains completely inhibits lysis by both primary and secondary CTL generated in the absence of antibody. In contrast, the a3 domain antibody did not inhibit secondary CTL (Figs. 5 B and 1 B) as effectively as it inhibited the activity of primary CTL (Figs. 5 A and 1 A) . Secondary CTL from mice injected with the a3 domain antibody at the time of grafting were even less inhibited by 28-14-8 ( Fig.  5 C) than secondary CTL from mice that were not injected with antibody (Fig . 5  B) . The activity ofsecondary CTL generated in the presence of 28-14-8 both in vivo and in vitro was essentially noninhibitable by the addition of 28-14-8 (Fig . 5 D) . It is also interesting that the secondary CTL generated in the presence of 28-14-8 in vivo were not totally inhibitable with the al/a2 domain antibody 30-5-7 . This suggested either that these CTL have a higher affinity than those derived from animals Log Relative Fluorescence not treated with antibody, or alternatively, that a minor CTL population can recognize Ld in the presence of bound 30-5-7 . The effect of Lyt-2 antibody on the lysis by these CTL populations was also examined . It was found that although antibody to Lyt-2 almost totally inhibited primary CTL (Fig. 5 A) , the antibody had less inhibitory effect on secondary CTL (Fig . 5 B) and had very little effect on secondary CTL generated in the presence of 28-14-8 in vivo and in vitro (Fig . 5 D) . These results suggested that the addition of 28-14-8 antibody favored the generation of Lyt-2-independent, over Lyt-2-dependent, anti-Ld CTL.
Cells Expressing a Mutation in the a3 Domain Are Killed by Lyt-2-independent Secondary CTL but not Lyt-2-dependent Primary CTL. The observation that antibodies to the a3 domain enhanced the generation of Lyt-2-independent CTL raised the possibility that the residues of the a3 domain bound by the 28-14-8 antibody also contributed to the determinant recognized by the Lyt-2 molecule of CTL. If so, then Lyt-2-dependent CTL could not associate with target cells with antibody bound to the a3 domain because the antibody would prevent binding by the Lyt-2 molecule . In contrast, Lyt-2-independent CTL would not be inhibited by a3 domain antibody, and in addition, could kill target cells that have lost the determinant recognized by the Lyt-2 molecule .
Recently it was demonstrated that substitution of lysine for glutamic acid at residue 227 in the a3 domain of H-2D d abrogates binding of the H-213d a3 domain specific antibody, 34-2-12, and lysis by primary anti-Dd CTL (13, 14) . H-2Dd-specific antibody 34-5-8, (Fig . 6 ) . This indicates that qualitative and not quantitative differences account for the functional differences described below. We therefore examined whether secondary anti-Dd CTL, generated in the presence of antibody to the a3 domain, could kill cells transfected with the mutant Dd gene and whether such CTL were Lyt-2 independent. As shown in Fig. 7 , primary anti-D' CTL did not kill cells expressing the mutant H-2Dd gene, 88 .15.29 (Fig .  7 E) . Furthermore, the lysis of the cells expressing wild-type H-2Dd was inhibited by antibody to the a3 domain of Dd (34-2-12) and by antibody to Lyt-2 (Fig . 7 A) . In contrast, secondary anti-Dd CTL generated in the presence of 34-2-12 in vivo and in vitro killed cells expressing the mutant or the wild-type H-2Dd gene equally well and this lysis was not inhibited by 34-2-12 and only weakly inhibited by antibody to Lyt-2 (Figs. 7, D and H) . To generate this Lyt-2-independent CTL population it was necessary to include the antibody in vitro since in vivo treatment alone was insufficient (Figs. 7, C and G) . The observation that cells expressing the mutant H-2Dd gene were killed by Lyt-2-independent CTL generated in a secondary response, but were not killed by Lyt-2-dependent primary CTL, suggested that the effect of the mutation in the H-2Dd gene was destruction of the determinant recognized by Lyt-2 . Consistent with this interpretation, lysis of 88 .15.28 by a subpopulation of secondary CTL generated in the absence of antibody, was not inhibited by antibody to 34-2-12 or anti-Lyt-2 ( Fig . 7 B) and it is this subpopulation of CTL that is capable of lysing the mutant R8 .15 .29 ( Fig. 7 F) . Cells Expressing a Mutation in the a3 Domain Fail to Elicit a Primary In Vitro CTL Response. The data presented thus far demonstrate that the Dd lys mutant is not recognized by primary CTL generated against the wild-type Dd glu molecule. However, the Dd lys molecule is recognized by anti-Dd CTL generated in secondary responses to wild-type Dd, especially when they are generated in the presence of mAb to the a3 domain . We therefore wanted to determine whether a CTL response could be generated using the Dd lys mutant as the stimulating antigen. If the mutation in the a3 domain resulted in secondary conformational effects on the al/a2 domains that abrogated recognition by primary CTL, then the mutant Dd lys molecule should be capable of eliciting a CTL response specific for Dd lys. If, however, the mutation prevents a necessary interaction between Lyt-2 and the a3 domain for the generation of primary in vitro CTL, then the Dd lys antigen might not stimulate a primary response in vitro.
To test whether Dd lys can stimulate a primary response, naive (C3H .OL x BALB .K)F1 spleen cells were stimulated with irradiated L cells expressing the wildtype (L .D' glu) or mutant (L .Dd lys) Dd molecule . This response is confined to H-2D' since these FI responder spleen cells express antigens encoded by both the C3H background and the H-2k haplotype. Thus the only determinants recognized by the Ft responders on these L cell transfectants should be located on the Dd lys or Dd glu molecule respectively. When analyzed by FMF, the L.Dd glu and L.Dd lys transfectants expressed equivalent amounts of Dd molecule as measured by their ability to bind the al/a2-reactive mAb 34-5-8 (data not shown) . The Fl anti-L .Dd effectors were tested on "Cr-labeled R8 .15 transfectants, since these cells serve as better targets than the L cell transfectants. As shown in Fig. 8 A, the wild-type Dd glu molecule elicited a strong CTL response which was almost completely inhibited by antibody to Lyt-2. Consistent with earlier findings (Fig. 7 and reference 14) , these anti Dd -glu effectors showed only weak cytotoxicity on mutant DI-lys antigens and this lysis was not inhibited by anti-Lyt-2 (Fig. 8 B) . In contrast, cells expressing the mutant Dd lys molecules failed to stimulate a primary CTL response when assayed (Fig . 8) . This observation provides additional evidence that the a3 domain is involved in Lyt-2 recognition in primary CTL responses.
Discussion
Characterization of the TCR on subclasses of T cells has led to the observation that the same Va and Vß chains can be used in receptors restricted by or specific for class I or class II MHC products (25) (26) (27) (28) (29) . Since the distinction of MHC class by T cells cannot be explained by the usage of nonoverlapping TCR a and ß gene pools, an additional feature of this interaction must provide the basis for the differential recognition . The T cell accessory molecules Lyt-2 (CD8) and L3T4 (CD4) have been implicated as playing a key role in distinguishing class I from class II molecules. A stringent correlation exists between the T cell subset phenotype and the class of MHC gene products recognized by the TCR . The Lyt-2'/CD8' T cells interact with targets expressing class I MHC antigens and the L3T4''/CD4 + T cells interact with targets expressing class II MHC antigens (11, (30) (31) (32) .
The functional involvement of the Lyt-2 surface antigen in T cell recognition of class I was first recognized by the demonstration that antibody to Lyt-2 blocks CTL activity (6, 7) . It was later proposed that the Lyt-2 receptor interacts with monomorphic determinants on the MHC class I molecules and thus facilitates low-affinity interactions between the TCR and the class I molecule (11, 12) . Several reports provide evidence that L3T4/CD4 can enhance T cell responsiveness especially when antigen is limiting and suggest that this is mediated, at least in part, by binding L3T4/CD4 to the class II molecule (33-37) as proposed earlier (11) . Thus, both Lyt-2 and L3T4 are thought to perform an adhesive function, facilitating the TCR MHC interaction . However, it has become increasingly evident that these accessory molecules are involved with additional functions required for the regulation of T cell activation that are independent of MHC antigens (38) (39) (40) (41) (42) (43) and that they may not always be essential for T cell function (44) . There is also recent evidence that activation results when CD4 or CD8 associates with the appropriate TCR on the cell surface (45) (46) (47) (48) . These studies also suggest that this is accomplished by the TCR and accessory molecule binding to the same MHC molecule . Therefore, these accessory molecules may facilitate T cell function through a multistep process, part of which involves recognition of a monomorphic determinant on the MHC molecule .
Since T cells that express the Lyt-2 phenotype are associated with class I recognition and antibodies to Lyt-2 can interfere with this recognition it is plausible that the Lyt-2 molecule on the T cell interacts with a monomorphic determinant on the class I molecule on the target cell, thus providing an MHC class I-specific recognition step . Here we present evidence that Lyt-2 recognizes a monomorphic determinant in the a3 domain of the class I molecule and that this is a distinct site from the one recognized by the TCR. Furthermore, our data suggest that mAb to class I can be used to specifically block either Lyt-2 or TCR recognition. These conclusions are based on three lines of evidence . First, mAbs to the al/a2 and a3 class I domains show synergism in their ability to enhance Ld-or DI-disparate skin grafts. Second, a correlation was found between the ability of mAb to a3 and Lyt-2 to block in vitro CTL responses . Furthermore, mAb to a3 were used to skew the response such that it was resistant to inhibition by mAb to a3 and correspondingly less inhibitable by antibody to Lyt-2. The third and most direct evidence supporting the conclusion that Lyt-2 recognizes an a3 determinant is based on the experiments using a cell line expressing a mutant Dd (R8.15 Dd lys) that contains a single amino acid substitution of glu to lys at residue 227 in the a3 domain . It is noteworthy that position 227 of class I molecules is highly conserved, when comparing available sequences, not only in mice but in rat and human as well (compiled in reference 49). Cells expressing the mutant R8 .15 Dd lys molecule were not lysed by primary CTL generated against wild-type Dd molecules (13, 14 ; Fig. 7 E) , and the weak lysis of the mutant cell line observed in secondary responses to Dd (13, Fig. 7 F) was significantly less inhibitable by mAb to a3 or Lyt-2 when compared with lysis on control R8 .15 Dd glu targets. However, when mAb to a3 was used both in vivo and in vitro, equal lysis of mutant and wild-type targets by these CTL was observed and this lysis was not inhibited by antibody to a3 and was only slightly inhibited by antibody to Lyt-2. Furthermore, cells expressing the mutant Dd lys molecule failed to stimulate a primary CTL response. Therefore, these data suggest that the Dd lys mutant has lost its ability to be recognized by Lyt-2.
This conclusion would obviously not be justified if secondary effects resultingfrom this mutation at position 227 influence the al/a2 TCR binding site. We feel this possibility is highly unlikely for the following reasons. First, the binding of mAbs to determinants in the al and/or a2 domains of the wild-type and mutant Dd molecules is indistinguishable as measured by fluorometry (14, Fig. 6 ) . Second, T cells whose recognition is Lyt-2-independent, such as the hybridoma 3DT52.5 .8 (14) or the bulk CTL culture shown in Fig. 7 , give equal responses on mutant and wildtype targets. Third, based on other structural comparisons, the distance separating residue 227 from the peptide binding site makes the possibility of a secondary interaction unlikely. The recent three-dimensional structure of HLA-A2 revealed that residue 227 is on the surface, but a considerable distance away from the peptide binding site formed by the a1 and a2 domains (Dr. D. Wiley, personal communication). The fourth and most direct evidence that the Dd lys mutation does not alter TCR recognition of the al/a2 binding site is that cells expressing this mutation do not elicit a primary CTL response (Fig . 8) . If secondary conformational effects of the mutation were responsible for the observed failure of primary CTL to kill cells expressing the mutant Dd molecule then cells expressing this mutant molecule should stimulate a primary CTL response specific for the Dd lys and not the Dd glu molecule . As shown in Fig. 8 , cells expressing the mutant Dd lys molecule, in contrast to cells expressing the Dd glu molecule, failed to elicit a primary response . This result suggested that the Dd lys mutation affected a recognition site of primary CTL that is distinct from the al/a2 site on class I molecules recognized by the TCR. In total, these data strongly support the hypothesis that residue 227 is an integral part of the Lyt-2 binding site on class I molecules.
The results reported here raise several interesting questions concerning in vivo and in vitro recognition of class I molecules. For example, what is the nature of the synergism that results when a combination of antibodies is used to prolong class 1-disparate graft survival since either antibody alone has a minimal effect? The results of in vivo antibody blocking studies are obviously more complex since antibodies to the al/a2 domain (30-5-7 for Ld) are clearly more proficient at abrogating the in vitro response than the in vivo response. This disparity is likely due to accessibility and time constraint differences between the in vitro and in vivo assays . Perhaps the in vivo situation allows enough time for CTL clones to be generated that displace the antibody or recognize the class I molecule al/a2 domains in the presence ofbound antibody. Consistent with this conclusion are the marked differences seen in the ability of several different antibodies to block the in vitro response (50) . Therefore, the relatively poor in vivo blocking of antibodies to al/CLL2, such as 30-5-7, could be explained by the generation of CTL clones capable of class I recognition in the presence of antibody. Then the synergism of antibody-induced graft enhancement could be explained ifthese aforementioned CTLs are largely Lyt-2 dependent and thus inhibitable with antibody to the a3 domain. Another question raised by these studies is whether the Lyt-2+ T helper cell or the Lyt-2 + CTL (or both) is blocked in vivo since both cell types appear to be involved in the rejection of skin allografts differing at a single class I locus (51) . At the effector cell level, although there was a good correlation between inhibition by antibodies to a3 and Lyt-2, more inhibition was consistently seen with antibodies to Lyt-2 than with antibodies to a3 . This suggests that a function in addition to recognition is provided by the Lyt-2/a3 interaction, such as signal transduction or TCR modulation (45, 46) . This interpretation could also explain the partial inhibition of the lysis of cells expressing the mutant Dd by antibodies to Lyt-2 (Fig. 7) .
In conclusion, the results reported here demonstrate that mAbs to class I molecules can be used to selectively block distinct T cell recognition signals. Specifically, mAbs to determinants in the a 1/a2 domain block TCR recognition, whereas mAbs to determinants in the a3 domain block Lyt-2 recognition. This observation thus provides a method whereby specific sites on the ligand or class I molecule can be blocked to prevent either Lyt-2 or TCR recognition. For in vitro assays this observation can be used to define the precise cellular and molecular interactions involved in allogeneic, and self-restricted hapten-specific or virus-specific T cell responses. For in vivo responses, our findings suggest that mAb to class I can be used to specifically abrogate recognition of foreign tissue allografts . This blocking of in vivo recognition is in contrast with most of the previous reports of allograft enhancement by antibodies because it is mediated by antibodies to class I and not class II molecules. The extent of prolongation of graft survival that we observed is also greater than that obtained with antibodies to class II molecules. Furthermore, in the system reported here the antibodies used for blocking are exclusively specific for antigens of the allograft and not the host . Thus, this approach is an exquisitely specific way to abolish recognition of tissue transplants.
Summary
The involvement of the different domains of the MHC class I molecule in CTL recognition was investigated . mAbs specific for the al/a2 domains of H-2Ld interfered with both the primary and secondary generation and effector function of in vitro Ld -specific CTL. mAbs specific for the a3 domain of H-2Ld interfered with the generation and function of primary in vitro Ld-specific CTL; however, there was no effect on the in vitro generation of secondary CTL and only partial inhibition oftheir function . In vivo treatment with graft-specific antibodies to both the a3 domain and the a1/a2 domains together resulted in a dramatic enhancement of Ld-or Dd-disparate skin grafts, whereas the individual mAbs showed minimal effects. This suggested that the class I a3 domain is recognized by alloreactive CTL. Several approaches were undertaken to examine whether recognition of the a3 domain determinants is mediated by the Lyt-2 molecule . When mAbs specific for the a3 domain of either H-2L d or H-21)d were used in vivo and in vitro, the resulting CTL population was not inhibited by antibody to the a3 domain and was only partially inhibited by antibody to Lyt-2. We therefore observed a correlation between the effects of antibody to the class I a3 domain of the target molecule and antibody to the Lyt-2 molecule on the CTL. To further test the relationship between CTL recognition of the a3 domain and the involvement of Lyt-2, we used a cell expressing a mutation in the a3 domain of the Dd molecule . The mutation resulted in a single amino acid substitution of glu to lys at residue 227 of the a3 domain. Consistent with an earlier report, cells expressing the mutant Dd lys molecule were not lysed by CTL from a primary stimulation against the wild-type Dd glu molecule . However, this same cell line was killed by the Lyt-2-independent secondary DI-specific CTL generated in the presence of antibody to the a3 domain in vivo and in vitro. Furthermore, cells expressing the mutant Dd lys molecule failed to stimulate a primary response. In conclusion, several independent lines of evidence indicate that residues in the a3 domain of the class I molecule are involved in recognition by the Lyt-2 molecule, and that Lyt-2-mediated recognition can be specifically blocked using mAb to determinants in the 0 domain.
